Name: Taysha Gene Therapies, Inc. (TSHA) Financial Statements
Creator: FinSpry

Taysha Gene Therapies Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Taysha Gene Therapies, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	8.33	15.45	2.50	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	8.33	15.45	2.50	0.00	0.00
Operating Expenses
Research & Development	66.00	56.78	91.17	131.94	31.89
Selling, General & Administrative	28.95	30.05	37.36	41.32	11.11
Operating Expenses	94.95	86.83	128.53	173.27	43.00
Operating Income	-86.62	-71.37	-162.45	-173.27	-43.00
Other Income/Expense
Interest Income	6.94	3.57	0.25	0.17	0.05
Interest Expense	0.10	5.00	3.80	1.43	-0.03
Other Income/Expense	-9.52	-38.77	-36.44	0.00	17.03
Income
Income Before Tax	-89.30	-111.57	-166.01	-174.52	-60.01
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-89.30	-111.57	-166.01	-174.52	-60.01
Net Income - Continuous Operations	-89.30	-111.57	-166.01	-174.52	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-87.95	-105.20	-161.04	-172.60	-59.97
EBIT	-89.20	-106.57	-162.22	-173.10	-59.98
Depreciation & Amortization	1.25	1.37	1.17	0.49	0.01
Earnings Per Share
Basic EPS	-	-1.00	-4.00	-5.00	-3.00
Diluted EPS	-	-1.00	-4.00	-5.00	-3.00
Basic Shares Outstanding	250.13	116.12	43.95	37.65	17.67
Diluted Shares Outstanding	250.13	116.12	43.95	37.65	17.67